|Bid||40.00 x 800|
|Ask||56.00 x 900|
|Day's range||45.88 - 46.92|
|52-week range||41.32 - 58.00|
|Beta (5Y monthly)||0.28|
|PE ratio (TTM)||19.79|
|Earnings date||25 Jul 2022 - 29 Jul 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||52.53|
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
HILDEN, Germany & GERMANTOWN, Md., May 16, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.
If you want to know who really controls Qiagen N.V. ( NYSE:QGEN ), then you'll have to look at the makeup of its share...